Immunology and Biotherapies
38.0K views | +0 today
Follow
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies
Scoop.it!

Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability - Online First - Springer

Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability - Online First - Springer | Immunology and Biotherapies | Scoop.it
Abstract

The convergence of advanced understanding of biology with chemistry has led to a resurgence in the development of antibody-drug conjugates (ADCs), especially with two recent product approvals. Design and development of ADCs requires the synergistic combination of the monoclonal antibody, the linker and the payload. Advances in antibody science has enabled identification and generation of high affinity, highly selective, humanized or human antibodies for a given target. Novel linker technologies have been synthesized and highly potent cytotoxic drug payloads have been created. As the first generation of ADCs utilizing lysine and cysteine chemistries moves through the clinic and into commercialization, second generation ADCs involving site specific conjugation technologies are being evaluated and tested. The latter aim to be better characterized and controlled, with wider therapeutic indices as well as improved pharmacokinetic-pharmacodynamic (PK-PD) profiles. ADCs offer some interesting physicochemical properties, due to conjugation itself, and to the (often) hydrophobic payloads that must be considered during their CMC development. New analytical methodologies are required for the ADCs, supplementing those used for the antibody itself. Regulatory filings will be a combination of small molecule and biologics. The regulators have put forth some broad principles but this landscape is still evolving.


Via Krishan Maggon
Krishan Maggon 's curator insight, May 24, 2015 1:57 AM
Pharmaceutical ResearchMay 2015Date: 19 May 2015Antibody-Drug Conjugates: Design, Formulation and Physicochemical StabilitySatish K. Singh, Donna L. Luisi, Roger H. Pak
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies
Scoop.it!

Antibody–drug conjugates: targeted weapons against cancer | ANTI

Antibody–drug conjugates: targeted weapons against cancer | ANTI | Immunology and Biotherapies | Scoop.it
Antibody–drug conjugates: targeted weapons against cancer Luisa Iamele, Luca Vecchia, Claudia ScottiDepartment of Molecular Medicine, Unit of Immunology and General Pathology, University of Pavia, Pavia, PV, Italy All authors contributed equally...

Via Krishan Maggon
Krishan Maggon 's curator insight, February 11, 2015 3:52 AM
REVIEW  Antibody Technology JournalAntibody–drug conjugates: targeted weapons against cancer         AbstractFulltextMetricsGet Permission

Authors Iamele L, Vecchia L, Scotti C

Published Date January 2015 Volume 2015:5 Pages 1—13

DOI http://dx.doi.org/10.2147/ANTI.S52914

Received 11 September 2014, Accepted 22 November 2014, Published 9 January 2015

Approved for publication by Dr Shixia Wang

Luisa Iamele, Luca Vecchia, Claudia Scotti

Department of Molecular Medicine, Unit of Immunology and General Pathology, University of Pavia, Pavia, PV, Italy

GLG Pharma's curator insight, February 17, 2015 7:44 AM

Good review of how antibody conjugates work.